Area of research
Molecular Biology · Nephrology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Dermatological and Skeletal Disorders, and Alzheimer's disease research and treatments.
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Sex-related Differences In Cardiac Involvement In Wild-type Transthyretin Amyloidosis
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable
Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs